{"acquisitions":[],"changes":[],"country":"DE","description":"Tubulis develops antibody-drug conjugate therapeutics combining proprietary linker chemistry with new payloads for solid tumors. Patients with treatment-resistant solid tumors are the eventual target. Tubulis advances internal pipeline assets alongside partnerships with pharma companies.","domain":"tubulis.com","employees":null,"founded":2019,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":48.10774,"lng":11.460445,"location":"Munich, Germany","multiples":[],"name":"Tubulis","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":332640000,"connectionsAmong":[],"currency":"EUR","date":"2025-10-15","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"tubulis-com-2025-10-15-c","source":{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":"series-c","url":null}],"slug":"tubulis-com","sources":[{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"tubulis.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://tubulis.com"},{"fact":"description","publisher":"tubulis.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://tubulis.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["Apache HTTP Server","jQuery Migrate","Elementor 4.0.9","WordPress","PHP","MySQL","jquery 3.7.1","apache"],"totalRaisedUsd":361800000,"traction":[],"updatedAt":"2026-05-07","valuations":[]}